Perspective Therapeutics (CATX) Operating Income (2010 - 2026)
Perspective Therapeutics (CATX) posted Operating Income of -$28.3 million for Q1 2026, down 29.54% sequentially from -$21.8 million in Q1 2025, and down 29.54% YoY from -$40.1 million in Q1 2025.
Perspective Therapeutics (CATX) Operating Income (2010 - 2026) Analysis & Trends
Perspective Therapeutics has reported Operating Income for 17 years, with the latest figure at -$28.3 million in Q1 2026.
- Quarterly Operating Income fell 29.54% year-over-year to -$28.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$113.7 million (down 14.06% YoY) and the FY2025 annual result came in at -$113.6 million, down 24.95% from the prior year.
- Operating Income retreated to -$28.3 million in Q1 2026 per CATX's latest filing, from -$21.8 million in the prior quarter.
- Over five years, Operating Income peaked at -$1.4 million in Q1 2022 and troughed at -$45.0 million in Q4 2024.
- A 5-year average of -$14.3 million and a median of -$10.7 million in 2023 frame the typical range for Operating Income.
- The widest YoY moves for Operating Income: up 26.79% in 2023, down 609.38% in 2023.
- Over 5 years, Operating Income stood at -$5.6 million in 2022, then plunged by 107.72% to -$11.7 million in 2023, then plunged by 285.27% to -$45.0 million in 2024, then surged by 51.47% to -$21.8 million in 2025, then fell by 29.54% to -$28.3 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$28.3 million, -$21.8 million, and -$45.0 million for Q1 2026, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 1.69 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 1.66 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 1.87 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 1.18 Bn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 513.20 Mn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 318.30 Mn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 739.00 Mn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 989.17 Mn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 285.80 Mn |
| 10 | Perspective Therapeutics | 389.10 Mn | 389.10 Mn | - | -29.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -29.26 Mn |
| Mar 31, 2026 | -28.28 Mn |
| Mar 31, 2025 | -21.83 Mn |
| Dec 31, 2024 | -44.98 Mn |
| Sep 30, 2024 | -18.63 Mn |
| Jun 30, 2024 | -14.26 Mn |
| Mar 31, 2024 | -13.01 Mn |
| Dec 31, 2023 | -11.68 Mn |
| Sep 30, 2023 | -9.75 Mn |
| Jun 30, 2023 | -9.75 Mn |
| Mar 31, 2023 | -9.76 Mn |
| Dec 31, 2022 | -5.62 Mn |
| Sep 30, 2022 | -7.69 Mn |
| Jun 30, 2022 | -3.48 Mn |
| Mar 31, 2022 | -1.38 Mn |
| Dec 31, 2021 | -1.64 Mn |
| Sep 30, 2021 | -2.27 Mn |
| Jun 30, 2021 | 1.35 Mn |
| Mar 31, 2021 | -766,000.00 |
| Dec 31, 2020 | -873,000.00 |